Nele Fourneau

729 total citations
14 papers, 388 citations indexed

About

Nele Fourneau is a scholar working on Molecular Biology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Nele Fourneau has authored 14 papers receiving a total of 388 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Genetics and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Nele Fourneau's work include Chronic Lymphocytic Leukemia Research (6 papers), Histone Deacetylase Inhibitors Research (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Nele Fourneau is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Histone Deacetylase Inhibitors Research (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Nele Fourneau collaborates with scholars based in United States, Belgium and France. Nele Fourneau's co-authors include Peter Hellemans, Johan W. Smit, Sriram Balasubramanian, Anas Younes, Yasuhiro Oki, Franck Morschhauser, Jason R. Westin, Jessica Vermeulen, Sandy Amorim and Bénédicte Hivert and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Nele Fourneau

13 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nele Fourneau United States 8 217 182 145 143 60 14 388
Bishan Ye United States 5 234 1.1× 165 0.9× 161 1.1× 71 0.5× 70 1.2× 7 324
Hannelore Madle Germany 5 173 0.8× 142 0.8× 117 0.8× 159 1.1× 88 1.5× 6 347
Elena Ruíz-Ballesteros Spain 8 299 1.4× 164 0.9× 211 1.5× 174 1.2× 96 1.6× 8 468
Noelia Purroy Spain 10 136 0.6× 88 0.5× 159 1.1× 113 0.8× 123 2.0× 18 334
J. Kaitlin Morrison United States 8 254 1.2× 230 1.3× 134 0.9× 100 0.7× 37 0.6× 17 380
Nichola Webster United Kingdom 4 253 1.2× 152 0.8× 129 0.9× 56 0.4× 57 0.9× 9 296
Isabel Romero-Camarero Spain 7 175 0.8× 172 0.9× 73 0.5× 191 1.3× 88 1.5× 11 412
Kirsty Wienand United States 7 238 1.1× 233 1.3× 87 0.6× 93 0.7× 192 3.2× 15 399
Kerstin Dietze Germany 6 147 0.7× 137 0.8× 96 0.7× 125 0.9× 112 1.9× 8 319
Hsu-Ping Kuo United States 8 123 0.6× 186 1.0× 72 0.5× 174 1.2× 150 2.5× 10 409

Countries citing papers authored by Nele Fourneau

Since Specialization
Citations

This map shows the geographic impact of Nele Fourneau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nele Fourneau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nele Fourneau more than expected).

Fields of papers citing papers by Nele Fourneau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nele Fourneau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nele Fourneau. The network helps show where Nele Fourneau may publish in the future.

Co-authorship network of co-authors of Nele Fourneau

This figure shows the co-authorship network connecting the top 25 collaborators of Nele Fourneau. A scholar is included among the top collaborators of Nele Fourneau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nele Fourneau. Nele Fourneau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Moreno, Víctor, Ruth Perets, Nele Fourneau, et al.. (2022). A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors. Investigational New Drugs. 41(1). 93–104. 18 indexed citations
2.
Bruscaggin, Alessio, Lodovico Terzi di Bergamo, Valeria Spina, et al.. (2021). Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. Blood Advances. 5(22). 4674–4685. 17 indexed citations
3.
Hodkinson, Brendan P., Michael Schäffer, Joshua Brody, et al.. (2020). Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. Translational Oncology. 14(1). 100977–100977. 14 indexed citations
4.
Schäffer, Michael, Shalini Chaturvedi, Jan de Jong, et al.. (2020). Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study. Cancer Treatment and Research Communications. 25. 100235–100235. 3 indexed citations
5.
Hodkinson, Brendan P., Michael Schäffer, Joshua Brody, et al.. (2019). Abstract 4024: Phase 1/2a LYM1002 study of ibrutinib (ibr) + nivolumab (nivo): Exome and gene expression profiling (GEP) analyses by histology and responder status. Cancer Research. 79(13_Supplement). 4024–4024. 1 indexed citations
6.
Calvo, Emiliano, Víctor Moreno, Ruth Perets, et al.. (2019). A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 2527–2527. 9 indexed citations
7.
Moreau, Philippe, Thierry Façon, Cyrille Touzeau, et al.. (2016). Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma. Leukemia & lymphoma. 57(7). 1546–1559. 24 indexed citations
8.
9.
Venugopal, Balaji, Richard D. Baird, Rebecca Kristeleit, et al.. (2013). A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(15). 4262–4272. 97 indexed citations
10.
Leleu, Xavier, Cyrille Touzeau, Lotfi Benboubker, et al.. (2013). Phase Ib dose escalation study of oral quisinostat, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone for patients with relapsed multiple myeloma.. Journal of Clinical Oncology. 31(15_suppl). 8530–8530. 1 indexed citations
11.
12.
Younes, Anas, Ian W. Flinn, Jesús G. Berdeja, et al.. (2013). Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology. 31(15_suppl). 8502–8502. 11 indexed citations
13.
Baird, Richard D., B. Venugopal, Montserrat Blanco-Codesido, et al.. (2011). A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity.. Journal of Clinical Oncology. 29(15_suppl). 3024–3024. 1 indexed citations
14.
Postel‐Vinay, Sophie, Peter C.C. Fong, B. Venugopal, et al.. (2009). Preliminary results of an open-label phase I pharmacokinetic/pharmacodynamic study of JNJ26481585: Early evidence of antitumor activity. Journal of Clinical Oncology. 27(15_suppl). e13504–e13504. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bishan Ye Breakdown of academic impact, for papers by Hannelore Madle Breakdown of academic impact, for papers by Elena Ruíz-Ballesteros Breakdown of academic impact, for papers by Noelia Purroy Breakdown of academic impact, for papers by J. Kaitlin Morrison Breakdown of academic impact, for papers by Nichola Webster Breakdown of academic impact, for papers by Isabel Romero-Camarero Breakdown of academic impact, for papers by Kirsty Wienand Breakdown of academic impact, for papers by Kerstin Dietze Breakdown of academic impact, for papers by Hsu-Ping Kuo
Rankless by CCL
2026